【佳學基因檢測】EMT在腫瘤進展和轉(zhuǎn)移中的分子機制和治療策略

dna檢測一次多少錢分析

分析看到《J Hematol Oncol》在.?2022 Sep 8;15(1):129.發(fā)表了一篇題目為《EMT在腫瘤進展和轉(zhuǎn)移中的分子機制和治療策略》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由Yuhe Huang?#,?Weiqi Hong?#,?Xiawei Wei?等完成。促進了腫瘤的正確治療與個性化用藥的發(fā)展，進一步強調(diào)了基因信息檢測與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究內(nèi)容關(guān)鍵詞：

循環(huán)腫瘤細胞,上皮-間質(zhì)轉(zhuǎn)化,轉(zhuǎn)移,腫瘤干性

腫瘤靶向治療基因檢測臨床應用結(jié)果

上皮-間質(zhì)轉(zhuǎn)化（EMT）是正常胚胎發(fā)育和組織再生的重要過程。然而，EMT 的異常再激活與腫瘤細胞在癌癥進展和轉(zhuǎn)移過程中的惡性特性相關(guān)，包括促進遷移和侵襲性、增加腫瘤干性以及增強對化學療法和免疫療法的抵抗力。 EMT 受到一個復雜網(wǎng)絡的嚴格調(diào)控，該網(wǎng)絡由多種內(nèi)在和外在因素協(xié)調(diào)，包括多種轉(zhuǎn)錄因子、翻譯后控制、表觀遺傳修飾和非編碼 RNA 介導的調(diào)控。在這篇綜述中，我們描述了 EMT 過程中涉及的分子機制、信號通路和腫瘤發(fā)生的階段，并討論了 EMT 的動態(tài)非二元過程及其在腫瘤轉(zhuǎn)移中的作用。賊后，我們總結(jié)了 EMT 中化療和免疫治療面臨的挑戰(zhàn)，并提出了針對 EMT 的腫瘤治療策略。上皮-間質(zhì)轉(zhuǎn)化；轉(zhuǎn)移;腫瘤干性。

腫瘤發(fā)生與反復轉(zhuǎn)移國際數(shù)據(jù)庫描述：

Epithelial-mesenchymal transition (EMT) is an essential process in normal embryonic development and tissue regeneration. However, aberrant reactivation of EMT is associated with malignant properties of tumor cells during cancer progression and metastasis, including promoted migration and invasiveness, increased tumor stemness, and enhanced resistance to chemotherapy and immunotherapy. EMT is tightly regulated by a complex network which is orchestrated with several intrinsic and extrinsic factors, including multiple transcription factors, post-translational control, epigenetic modifications, and noncoding RNA-mediated regulation. In this review, we described the molecular mechanisms, signaling pathways, and the stages of tumorigenesis involved in the EMT process and discussed the dynamic non-binary process of EMT and its role in tumor metastasis. Finally, we summarized the challenges of chemotherapy and immunotherapy in EMT and proposed strategies for tumor therapy targeting EMT.Keywords:?Circulating tumor cells; Epithelial–mesenchymal transition; Metastasis; Tumor stemness.